Olema reports interim Phase 1b/2 data: palazestrant + ribociclib shows 85% CBR in ER+/HER2- mBC

Olema Pharmaceuticals, Inc.

Combination well tolerated in 50 patients; no new safety signals and no clinically meaningful drug-drug interaction.
Clinical benefit rate of 85% (11/13) overall; 83% in ESR1-mutant, 86% in wild-type, 83% in prior CDK4/6i patients.
Partial responses observed in 5 of 23 evaluable patients (2 confirmed, 3 unconfirmed); 66% remain on treatment.
Study fully enrolled at 60 patients; data support continued development for first-line ER+/HER2- advanced breast cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.